FDA Approves IND for Ph 1 Trial of ABL206 (NEOK001)
Sang Hoon Lee, CEO of ABL Bio, stated, “With ABL206, our first bispecific ADC candidate, entering Phase 1 clinical trials, we have taken the first step in our journey toward developing next-generation ADCs. We are very pleased to have successfully obtained IND approval without any issues, thanks to the close collaboration and dedicated R&D efforts of ABL Bio and NEOK Bio. We will continue to accelerate our research and development to introduce a diverse range of next-generation ADC candidates following ABL206.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.